137 related articles for article (PubMed ID: 17275485)
1. Pharmacokinetics of neoral in stable renal transplant recipients with long-term diabetes mellitus.
Deel C; Nori U; Pescovitz MD; Govani MV
Transplant Proc; 2007; 39(1):109-14. PubMed ID: 17275485
[TBL] [Abstract][Full Text] [Related]
2. Reduced intrapatient variability of cyclosporine pharmacokinetics in renal transplant recipients switched from oral Sandimmune to Neoral.
Mendez R; Abboud H; Burdick J; Copley B; Freeman R; Batiuk TD; Cooney GF; Barbeito R
Clin Ther; 1999 Jan; 21(1):160-71. PubMed ID: 10090433
[TBL] [Abstract][Full Text] [Related]
3. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation.
Rodríguez E; Delucchi MA; Cano F; Valdebenito S; Castillo MC; Villegas R
Transplant Proc; 2005 Oct; 37(8):3354-7. PubMed ID: 16298594
[TBL] [Abstract][Full Text] [Related]
4. Limited sampling strategy for cyclosporine (Neoral) area under the curve monitoring in pediatric kidney transplant recipients.
Strong DK; Lai A; Primmett D; White CT; Lirenman DS; Carter JE; Hurley RM; Virji M; Ensom MH
Pediatr Transplant; 2005 Oct; 9(5):566-73. PubMed ID: 16176411
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery.
Banner NR; David OJ; Leaver N; Davis J; Breen J; Johnston A; Yacoub MH
Transpl Int; 2002 Dec; 15(12):649-54. PubMed ID: 12478413
[TBL] [Abstract][Full Text] [Related]
6. Investigation of the pharmacokinetics of cyclosporine in patients following long-term administration after a kidney transplant: comparison of Neoral and Sandimmune.
Takahara S; Ichimaru N; Kojima Y; Namba Y; Toki K; Shi Y; Yoshimura K; Matsumiya K; Nonomura N; Okuyama A
Transplant Proc; 2004 Mar; 36(2 Suppl):456S-460S. PubMed ID: 15041387
[TBL] [Abstract][Full Text] [Related]
7. Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral).
Jaksch P; Kocher A; Neuhauser P; Sarahrudi K; Seweryn J; Wisser W; Klepetko W
J Heart Lung Transplant; 2005 Aug; 24(8):1076-80. PubMed ID: 16102443
[TBL] [Abstract][Full Text] [Related]
8. Evolution of the therapeutic drug monitoring of cyclosporine.
Citterio F
Transplant Proc; 2004 Mar; 36(2 Suppl):420S-425S. PubMed ID: 15041378
[TBL] [Abstract][Full Text] [Related]
9. Correlation Between C2 and AUC(0-4) in Renal Transplant Patients Treated With Diltiazem.
Aros CA; Schneider HO; Flores CA; Ardiles LG; Alruiz PA; Jerez V; Mezzano SA
Transplant Proc; 2005 Apr; 37(3):1580-2. PubMed ID: 15866679
[TBL] [Abstract][Full Text] [Related]
10. C2 monitoring of cyclosporine in stable renal transplant patients results in lower costs and improved renal function.
Domínguez J; Fuenzalida D; Norambuena R; Pais E; Cortes Monroy G; Llanos R
Transplant Proc; 2005 Apr; 37(3):1583-5. PubMed ID: 15866680
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic.
Brunet M; Crespo M; Millán O; Serón D; Torregrosa V; Jiménez O; Moreso F; Martorell J; Grinyo JM; Oppenheimer F
Transplant Proc; 2007 Sep; 39(7):2160-2. PubMed ID: 17889124
[TBL] [Abstract][Full Text] [Related]
12. C2 and C0 values for monitoring cyclosporine therapy in stable heart transplant recipients.
Diciolla F; Scolletta S; Berti L; Maccherini M; Federici D; Bernazzali S; Lisi G; Chiavarelli M
Transplant Proc; 2005 Mar; 37(2):1355-9. PubMed ID: 15848719
[TBL] [Abstract][Full Text] [Related]
13. Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients.
Akhlaghi F; Gonzalez L; Trull AK
J Heart Lung Transplant; 2005 Dec; 24(12):2120-8. PubMed ID: 16364860
[TBL] [Abstract][Full Text] [Related]
14. C2 is an age-independent parameter for optimal cyclosporine exposure in long-term kidney transplant recipients.
Ferraresso M; Citterio F; Ghio L; Romagnoli J; Edefonti A; Berardinelli L; Castagneto M
Transplant Proc; 2004 Nov; 36(9):2656-8. PubMed ID: 15621115
[TBL] [Abstract][Full Text] [Related]
15. Two-hour postdose concentration: a reliable marker for cyclosporine exposure in adolescents with stable renal transplants.
John U; Ullrich S; Roskos M; Misselwitz J
Transplant Proc; 2005 Apr; 37(3):1608-11. PubMed ID: 15866686
[TBL] [Abstract][Full Text] [Related]
16. Three-years experience with Neoral C2 monitoring adjusted to a target range of 500-600 ng/ml in long-term renal transplant recipients receiving dual immunosuppressive therapy.
Carstens J
Scand J Urol Nephrol; 2008; 42(3):286-92. PubMed ID: 18432535
[TBL] [Abstract][Full Text] [Related]
17. A limited sampling strategy for the estimation of 12-hour cyclosporine neoral area under the curve in Chinese cardiac transplant recipients.
Wang CH; Ko WJ; Chou NK; Wang SS
Transplant Proc; 2004 Oct; 36(8):2390-2. PubMed ID: 15561259
[TBL] [Abstract][Full Text] [Related]
18. Clinical benefits of neoral C2 monitoring in the long-term management of renal transplant recipients.
Cole E; Maham N; Cardella C; Cattran D; Fenton S; Hamel J; O'Grady C; Smith R
Transplantation; 2003 Jun; 75(12):2086-90. PubMed ID: 12829917
[TBL] [Abstract][Full Text] [Related]
19. Hepatotoxicity associated with cyclosporine monitoring using C2 recommendations in adults renal recipients receiving ketoconazole.
Videla C; Vega J; Borja H
Transplant Proc; 2005 Apr; 37(3):1574-6. PubMed ID: 15866677
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of cyclosporine C2 levels in long-term stable renal allograft recipients.
Hu RH; Tsai MK; Lee PH
Transplant Proc; 2004 Sep; 36(7):2105-7. PubMed ID: 15518762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
